Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Prelude Therapeutics Incorporated before investing.

In this article, we go over a few key elements for understanding Prelude Therapeutics Incorporated’s stock price such as:

• Prelude Therapeutics Incorporated’s current stock price and volume
• Why Prelude Therapeutics Incorporated’s stock price changed recently
• Upgrades and downgrades for PRLD from analysts
• PRLD’s stock price momentum as measured by its relative strength

About Prelude Therapeutics Incorporated (PRLD)

Before we jump into Prelude Therapeutics Incorporated’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Want to learn more about Prelude Therapeutics Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Prelude Therapeutics Incorporated.

Prelude Therapeutics Incorporated’s Stock Price as of Market Close

As of April 07, 2026, 4:00 PM, CST, Prelude Therapeutics Incorporated’s stock price was $4.400.

Prelude Therapeutics Incorporated is up 19.57% from its previous closing price of $3.680.

During the last market session, Prelude Therapeutics Incorporated’s stock traded between $3.680 and $4.500. Currently, there are approximately 79.71 million shares outstanding for Prelude Therapeutics Incorporated.

Prelude Therapeutics Incorporated’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Prelude Therapeutics Incorporated Stock Price History

Prelude Therapeutics Incorporated’s (PRLD) price is currently up 28.66% so far this month.

During the month of April, Prelude Therapeutics Incorporated’s stock price has reached a high of $4.500 and a low of $3.270.

Over the last year, Prelude Therapeutics Incorporated has hit prices as high as $4.500 and as low as $0.610. Year to date, Prelude Therapeutics Incorporated’s stock is up 51.72%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Prelude Therapeutics Incorporated Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 07, 2026, there were 0 analysts who downgraded Prelude Therapeutics Incorporated’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Prelude Therapeutics Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Prelude Therapeutics Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Prelude Therapeutics Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Prelude Therapeutics Incorporated (PRLD) by visiting AAII Stock Evaluator.

Relative Price Strength of Prelude Therapeutics Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 07, 2026, Prelude Therapeutics Incorporated has a weighted four-quarter relative price strength of 58.52%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Prelude Therapeutics Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Prelude Therapeutics Incorporated Stock Price: Bottom Line

As of April 7, 2026, Prelude Therapeutics Incorporated’s stock price is $4.400, which is up 19.57% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Prelude Therapeutics Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.